Literature DB >> 9710347

Pharmacokinetics of vancomycin when administered during high flux hemodialysis.

E F Foote1, W B Dreitlein, C A Steward, T Kapoian, J A Walker, R A Sherman.   

Abstract

This study was undertaken to evaluate the pharmacokinetics of relatively high-dose vancomycin when administered during high-flux hemodialysis using a polysulfone membrane (F-80, Fresenius). Five noninfected, anuric patients received a single dose of 25 mg/kg of vancomycin infused during hemodialysis at a rate of one gram per hour and timed such that the end of the infusion coincided with the end of dialysis. Blood samples were drawn during the infusion, up to six hours after the end of dialysis and then prior to the next three dialysis treatments. Spent dialysate was collected during the infusion. Samples were analyzed using the EMIT assay. The percent of vancomycin lost during the first dialysis session ranged from 39.1 to 55.1% (mean, 45.7+/-6.4). The concentration of vancomycin at 6 hours after hemodialysis ranged from 18.2 to 45.1 mg/L (mean, 29.6+/-10.0 mg/l). Dialysis clearance ranged from 96.1 to 158.1 ml/min (mean, 130.7 +/-30.0 ml/min). One week after dosing, serum concentrations ranged from 8.14 mg/l to 10.1 mg/l (mean, 9.0+/-1.0 mg/l). This study suggests than an initial dose of 25 mg/kg of vancomycin, given during high-flux dialysis, may provide adequate serum concentrations in anuric hemodialysis patients for up to seven days. This dosing scheme reduces inconvenience to the patient and staff, and potentially can reduce nursing costs associated with post-dialysis administration; its cost is minimal. At this point, subsequent dosing is best determined by therapeutic drug monitoring.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9710347

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  8 in total

1.  Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration.

Authors:  Megan E DelDot; Jeffrey Lipman; Susan E Tett
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

2.  Predicting Maintenance Doses of Vancomycin for Hospitalized Patients Undergoing Hemodialysis.

Authors:  Wasim S El Nekidy; Maher M El-Masri; Greg S Umstead; Michelle Dehoorne-Smith
Journal:  Can J Hosp Pharm       Date:  2016-10-31

3.  Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis.

Authors:  Noha N Salama; Jonathan H Segal; Mariann D Churchwell; Jignesh H Patel; Lihong Gao; Michael Heung; Bruce A Mueller
Journal:  Clin J Am Soc Nephrol       Date:  2009-06-18       Impact factor: 8.237

4.  Determination of vancomycin and gentamicin clearance in an in vitro, closed loop dialysis system.

Authors:  Soo Min Jang; Katie E Cardone; Thomas D Nolin; Darius L Mason; Darren W Grabe
Journal:  BMC Nephrol       Date:  2014-12-20       Impact factor: 2.388

5.  Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration.

Authors:  Manuel Voigt; Michael Gebert; Ulrike Haug; Michael Hulko; Markus Storr; Adriana Boschetti-de-Fierro; Werner Beck; Bernd Krause
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

6.  Pharmacokinetics of Vancomycin in Pediatric Patients Receiving Intermittent Hemodialysis or Hemodiafiltration.

Authors:  Erin Chung; James A Tjon; Rosaleen M Nemec; Nadya Nalli; Elizabeth A Harvey; Christoph Licht; Winnie Seto
Journal:  Kidney Int Rep       Date:  2021-02-06

Review 7.  Clinical review: use of vancomycin in haemodialysis patients.

Authors:  Vincent Launay-Vacher; Hassane Izzedine; Lucile Mercadal; Gilbert Deray
Journal:  Crit Care       Date:  2002-06-10       Impact factor: 9.097

Review 8.  Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review.

Authors:  Anri Sawada; Kunio Kawanishi; Shohei Morikawa; Toshihiro Nakano; Mio Kodama; Mitihiro Mitobe; Sekiko Taneda; Junki Koike; Mamiko Ohara; Yoji Nagashima; Kosaku Nitta; Takahiro Mochizuki
Journal:  BMC Nephrol       Date:  2018-03-27       Impact factor: 2.388

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.